Who benefits most from omega-3 for dry eye?
The evidence points to several groups that are most likely to see improvement. People with meibomian gland dysfunction (MGD)—the most common cause of dry eye, where the oil glands in the eyelids don't produce enough oil to keep tears from evaporating—appear to be strong candidates. A randomized trial of 50 MGD patients found that those taking a high-dose DHA omega-3 supplement (1640 mg DHA plus 600 mg EPA daily) had significantly better tear break-up time (6.0 vs. 5.1 seconds) and lower MGD scores after 8 weeks compared to placebo [4]. This makes biological sense: omega-3s help improve the quality of the oil layer in tears, stabilizing the tear film.
Another group that clearly benefits are people with low baseline omega-3 levels. In a large trial of 470 visual display terminal users, 81% had a low omega-3 index (a measure of EPA and DHA in red blood cells) at the start. Those with the lowest levels (<4%) showed the greatest improvement in symptoms, tear osmolarity, and tear break-up time after 6 months of supplementation [2]. This suggests that if your diet is already rich in omega-3s, adding more may not help much—but if you're deficient, it can make a real difference.
Patients with dry eye after eye surgery also seem to benefit. Two randomized trials—one after cataract surgery (61 eyes) and one after LASIK (60 patients)—both found that adding omega-3 supplements to standard care improved tear production and reduced symptoms compared to placebo or standard care alone [3][7]. In the cataract study, tear osmolarity dropped significantly more in the omega-3 group (from 315 to 297 mOsm/L) than in the control group (from 317 to 311 mOsm/L) [3].
What does the evidence actually show about symptoms and signs?
The picture is mixed when you look across all studies. A 2020 Cochrane review—the gold standard for evidence synthesis—analyzed 34 randomized controlled trials involving 4,314 participants and found low-certainty evidence that omega-3 supplements may reduce dry eye symptoms, but the effect was small and inconsistent [6]. For example, the review found that long-chain omega-3 (EPA and DHA) produced only a modest improvement in symptoms (about 2.5 points on a 100-point scale) compared to placebo, which may not be noticeable to patients [6].
However, the same Cochrane review found moderate-certainty evidence that omega-3 supplements increase tear production (by about 0.7 mm on the Schirmer test) and low-certainty evidence that they reduce tear osmolarity (by about 18 mOsm/L) [6]. These are objective improvements in tear quality and quantity, even if the symptom relief is less dramatic. A separate 2014 trial of 64 patients found that just 30 days of omega-3 (360 mg EPA + 240 mg DHA daily) improved tear break-up time by 71% (from 3.9 to 5.7 seconds) and reduced symptom scores by 26% [8].
Importantly, the largest single study—the DREAM trial (535 participants)—found that while omega-3 improved some signs like tear break-up time and corneal staining, the effects were modest and not consistent across all measures [1]. And in a follow-up DREAM study, patients who stopped taking omega-3 after a year did not get worse, suggesting that the supplement may not be providing ongoing benefit for everyone [5].
What dose and duration work best?
The studies used a wide range of doses, but the most effective regimens appear to be those providing at least 600 mg of EPA and 300 mg of DHA daily, often split into two doses. The high-dose DHA study used 1640 mg DHA + 600 mg EPA daily [4], while the VDT user study used 720 mg EPA + 480 mg DHA daily (four capsules twice daily) [2]. The cataract surgery study used a similar dose (180 mg EPA + 120 mg DHA per capsule, four capsules daily) [3].
Duration matters too. Most positive studies lasted at least 1–3 months, with some showing benefits as early as 30 days [8]. The 6-month trials showed sustained improvements [2][9]. A 2021 study using a novel omega-3/omega-6 combination (1200 mg EPA, 300 mg DHA, 150 mg GLA) found that after 3 months, the most symptomatic patients (OSDI score >52) experienced a clinically meaningful 21-point drop in symptom scores [10].
It's worth noting that the placebo effect can be substantial in dry eye trials. In the 2021 combination study, even the placebo group (olive oil) saw a 7.8-point improvement in symptoms [10]. This underscores the importance of using well-designed placebo-controlled trials, which most of the studies here did.
About These Sources
This answer is built on 10 peer-reviewed studies — published from 2014 to 2023, 1 in Q1 journals, collectively cited 90 times — selected as the most relevant from 12 studies that passed quality screening, drawn from 48 papers retrieved from a database of over 500 million.
Sources used in this answer
Age Associations with Dry Eye Clinical Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study
In a secondary analysis of the DREAM trial (535 participants), increasing age was associated with worse tear break-up time, corneal staining, and tear osmolarity, especially in women, but symptoms did not worsen with age.
Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective?
In a randomized controlled trial of 470 visual display terminal users, omega-3 supplements (720 mg EPA + 480 mg DHA daily for 6 months) significantly improved symptoms, tear osmolarity, Schirmer test, tear break-up time, and goblet cell density compared to placebo; patients with the lowest baseline omega-3 index (<4%) benefited most.
Effects of adjuvant omega-3 fatty acid supplementation on dry eye syndrome following cataract surgery: A randomized clinical trial
In a randomized clinical trial of 61 eyes after cataract surgery, adding omega-3 supplements to conventional therapy significantly improved OSDI scores and tear break-up time compared to conventional therapy alone; tear osmolarity dropped significantly more in the omega-3 group (from 315 to 297 mOsm/L).
Effects of dietary high dose DHA omega-3 supplement in dry eye with meibomian gland dysfunction
In a prospective randomized double-masked placebo-controlled trial of 50 patients with meibomian gland dysfunction, high-dose DHA omega-3 (1640 mg DHA + 600 mg EPA daily for 8 weeks) significantly improved tear break-up time and MGD scores compared to placebo.
The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease.
In the DREAM extension study (43 patients), those who stopped taking omega-3 after 12 months did not have significantly worse dry eye outcomes over the next 12 months compared to those who continued, suggesting the benefit may be limited or not sustained.
Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease.
A 2020 Cochrane review of 34 RCTs (4,314 participants) found low-certainty evidence that long-chain omega-3 may slightly reduce dry eye symptoms and moderate-certainty evidence for a small increase in tear production; overall evidence was uncertain and inconsistent.
Oral Omega-3 Fatty Acid Supplementation for Laser In Situ Keratomileusis-Associated Dry Eye.
In a prospective open-label study of 60 LASIK patients, omega-3 supplementation (1.2 g/day for 12 weeks) significantly improved Schirmer scores and reduced conjunctival staining compared to vitamin E control, but tear break-up time was not significantly different.
Short-term consumption of oral omega-3 and dry eye syndrome.
In a randomized double-blind trial of 64 dry eye patients, 30 days of omega-3 (360 mg EPA + 240 mg DHA daily) improved tear break-up time by 71%, reduced OSDI scores by 26%, and increased Schirmer scores by 22% compared to placebo.
Oral omega-3 fatty acid treatment for dry eye in contact lens wearers.
In a randomized double-blind trial of 496 contact lens wearers, omega-3 supplements (twice daily for 6 months) significantly improved dry eye symptoms, lens wear comfort, tear break-up time, and conjunctival cytology compared to placebo.
Effect of a Novel Omega‐3 and Omega‐6 Fatty Acid Supplement on Dry Eye Disease: A 3‐month Randomized Controlled Trial
In a randomized double-masked trial of 50 participants with moderate to severe dry eye, a novel omega-3/omega-6 supplement (1200 mg EPA, 300 mg DHA, 150 mg GLA daily for 3 months) significantly improved symptoms in those with baseline OSDI >52, but objective signs did not change significantly.